Obesity may increase the long-term risk of disease progression in men on active surveillance for low-risk prostate cancer (PCa), according to study findings presented at the Canadian Urological Association annual meeting in St. John’s, Newfoundland. Read the article.
Brachytherapy for prostate cancer (PCa) is associated with favorable 15-year cancer-specific survival, particularly in patients with high-risk disease, a study found. In addition, brachytherapy patients who receive hormone therapy for more than 6 months have decreased all-cause survival. Read the article.